The Priority Review

Clinical trials Brief

Merck posts results of Phase III KEYNOTE-522 trial in triple negative breast cancer

The study enrolled 1,174 participants and compared pembrolizumab plus chemotherapy to placebo plus chemotherapy as neoadjuvant therapy, followed by pembrolizumab or placebo as adjuvant therapy. Results were first posted on ClinicalTrials.gov on October 22, 2026.

Primary source

ClinicalTrials.gov results record, October 22, 2026

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

Read the source clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation